Quetiapine-Induced Hypomania and its Association with Quetiapine/Norquetiapine Plasma Concentrations: A Case Series of Bipolar Type 2 Patients

International guidelines consider quetiapine at medium doses (300–400 mg/day) as valid options for the treatment of bipolar depression for the supposed lower risk of a switch to hypomania/mania than antidepressants. Norquetiapine is an active metabolite with antidepressant action. We describe three...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Drug Saf Case Rep
Egile Nagusiak: Rovera, C., Esposito, C. M., Ciappolino, V., Cattaneo, D., Baldelli, S., Clementi, E., Altamura, A. C., Buoli, M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer International Publishing 2017
Gaiak:
Case Series
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5653679/
https://ncbi.nlm.nih.gov/pubmed/29063217
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40800-017-0057-9
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak